Get startedLog in
    Picture of BioArctic AB logo

    BIOA B — BioArctic AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapHigh Flyer
    All News

    Brief: Bioarctic Receives European Substance Patent For Exidavnemab

    Picture of BioArctic AB logoBioArctic AB
    23/04/2025 12:47
    April 23 (Reuters) - BioArctic AB BIOAb.ST:

BIOARCTIC RECEIVES EUROPEAN SUBSTANCE PATENT FOR EXIDAVNEMAB

PATENT ENTERS INTO FORCE ON 14 MAY 2025 AND EXPIRES IN 2041, WITH POSSIBILITY OF EXTENSION UNTIL 2046.

Source text: ID:nWkr97T66G

Further company coverage: [BIOAb.ST]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on BioArctic AB

    See all news